Myriad Genetics published clinical evidence showing that the RiskScore analysis is a component of the MyRisk Hereditary Cancer Test that accurately predicts future breast cancer risk in over 650,000 women across multiple clinical studies with more than 15 years of follow up.
Public source
Publisher name
Public post
𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐕𝐚𝐥𝐢𝐝𝐚𝐭𝐞𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞. 𝐌𝐨𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐢𝐬𝐤 𝐀𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭. The RiskScore® analysis is a component of the MyRisk®…
Company
Myriad Genetics
Leading molecular diagnostic testing & precision medicine company dedicated to advancing health and well-being for all.
- Industry
- Biotechnology Research
- Location
- Salt Lake City, US
- Company size
- 1,001–5,000 employees
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs.
See moreLatest activity
Latest activity from Myriad Genetics
5 signals
Products & Services
Myriad Genetics expanded access to faster hereditary cancer testing for both endometrial and ovarian cancer patients.
People
Myriad Genetics employee Betsy Bailey joined Guardant Health Health as an Account Executive- Oncology.
Research & Knowledge
Myriad Genetics published a study of more than 8,000 women showing that an elevated RiskScore result is associated with increased adoption of risk-appropriate breast cancer screening and surveillance, including breast MRI, even when Tyrer-Cuzick is not elevated.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Starling Genomics
Starling Genomics published a new European study showing how polygenic risk scores are beginning to move from research into real-world breast cancer screening and prevention.
Research & Knowledge
Caris Life Sciences
Caris Life Sciences developed Caris MI Clarity™, a new approach to prognostic assessment in early-stage breast cancer trained and validated on TAILORx and NSABP B-42 clinical trial data, delivering independent risk insights across 15 years from a single diagnostic sample.
Research & Knowledge
Natera
Natera published a new public publication in Blood Neoplasia representing an important advancement in lymphoma ctDNA-MRD testing.
Research & Knowledge
SOPHiA GENETICS
SOPHiA GENETICS published real-world evidence showing nearly 4,800 patients across Spain accessing HRD testing without sending samples to a single lab.
Research & Knowledge
Ambry Genetics